News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

18.05.2011 | 110518_Epigenomics_AG_press_release_AGM

Berlin, Germany, May 18, 2011

Epigenomics AG (Frankfurt Prime Standard: ECX), the cancer molecular diagnostics company, today issued invitations to its Annual General Shareholders’ Meeting scheduled for June 28, 2011.

Among other items, the agenda includes a decision proposal by the Executive Board and the Supervisory Board to reduce the Company’s share capital according to Sections 229 et seqq. of the German Stock Corporation Act (AktG) concomitant with a 5:1 reverse stock split. The share capital would be reduced from the current total of EUR 44,092,085.00 to EUR 8,818,417.00, allocated to 8,818,417 shares outstanding. The difference of EUR 35,273,668.00 would be credited to the capital reserve, leaving shareholder’s equity and balance sheet total unchanged.

The reduction in share capital and the consolidation of the shares would serve in the full amount to offset depreciation and cover other losses.

With the release of its financial statements for 2010 on April 7, 2011, Epigenomics indicated that within the second half of 2011 its accrued losses according to German GAP may surpass half of the Company’s share capital. According to Sec. 92 Para. 1 of the AktG, this would trigger an immediate convocation of an Extraordinary Shareholders’ Meeting.

By the suggested reduction of the share capital an Extraordinary Shareholders’ Meeting could be avoided. Furthermore, the company expects that the measure will improve the key indicators per share, which may lead to an improved rating of Epigenomics’ shares. This would increase flexibility in potential future financial or strategic capital markets transactions. At the upcoming Annual General Shareholders’ Meeting Epigenomics’ Executive Board will report on the commercial and financial status of the Company and is available for questions by its shareholders.

On March 31, 2011, Epigenomics’ liquid assets amounted to EUR 23.5 million.

Further details on the upcoming Annual General Shareholder‘s Meeting 2011 are available at

Contact Epigenomics AG

Dr. Achim Plum
Sen. VP Corporate Development
Epigenomics AG
Tel +49 (0) 30 24345 368

About Epigenomics

Epigenomics is a molecular diagnostics company developing and commercializing a pipeline of proprietary products for cancer. The Company’s products enable doctors to diagnose cancer earlier and more accurately, leading to improved outcomes for patients. Epigenomics’ lead product, Epi proColon®, is a blood-based test for the early detection of colorectal cancer, which is currently marketed in Europe and is in development for the U.S.A. The Company’s technology and products have been validated through multiple partnerships with leading global diagnostic companies including Abbott, QIAGEN, Sysmex, and Quest Diagnostics. Epigenomics is an international company with operations in Europe and the U.S.A.

Epigenomics legal disclaimers. This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.